Toggle light / dark theme

Would you be okay to have these injected in you?


Engineers at Cornell University developed a microscopic robot – so small it’s invisible to the naked eye – that walks. It’s so tiny that ten could fit within a period. The team says they can manufacture one million of the robots per week.

The new robot is essentially a microchip on four origami-inspired legs that can be activated by lasers. It was designed to crawl inside the human body, find and eliminate diseases. It can be steered by beaming a laser at its feet, which causes their leg to bend.

Itai Cohen and Paul McEuen Labs, leaders of this invention, envisions them as a beneficial medical tool to do things like hunt down and destroy cancer cells. The micro-bots are so small they can be injected into the body.

Sean Eddy stood awkwardly next to fossil exhibits at a 2015 wine reception at the Harvard Museum of Natural History. He was new to the University and didn’t know a soul. Then up strolled a smiling Rob Lue, who “started telling me about his new work on data-driven urban planning in Paris, and we immediately hit it off,” Eddy recalls.

The Ellmore C. Patterson Professor of Molecular and Cellular Biology and department chair would eventually come to learn that Lue was a highly regarded researcher, an energetic leader in innovative teaching, and roundly cherished for his warm and generous spirit. “Rob was an optimist with a passion that would draw you in and get you talking with him about the good things in the world — art and books and education — and how we could make the world an even better place together,” Eddy said. “He saw the best in people.”

Lue, who died Wednesday at 56 from cancer, had an impact felt deeply among undergraduates on campus and beyond. He was professor of the practice in the Department of Molecular and Cellular Biology, founding faculty director of HarvardX, faculty director of the Harvard Ed Portal, Richard L. Menschel Faculty Director of the Derek Bok Center for Teaching and Learning, UNESCO Chair on Life Sciences and Social Innovation, and faculty director and principal investigator of LabXchange.

This was the second drone flash mob event this year, aimed at invigorating and encouraging the public to overcome the economic difficulties and COVID-19 challenges.

More than 120 of new cases were reported on Friday in densely populated Seoul metropolitan area, where officials have struggled to stem transmissions tied to various places, including hospitals, nursing homes, churches, schools, restaurants and offices.

https://media.blubrry.com/drjohnday/p/drjohnday.com/podcasts/Podcast217.mp3 Podcast: Play in new window | DownloadSubscribe: Apple Podcasts | Android | RSS6 Foods to Reverse Aging with Lithium Could a microscopic dose of the psychoactive drug lithium, which occurs naturally in mineral water and certain foods, actually be the secret to less heart disease, better moods, and a longer life? In this article, I share how eating six foods may reverse aging with lithium.

The quiet shift in strategy, which brings the Vision Fund’s approach closer to that of a traditional venture capital investor, may ease concerns over big, bold bets going sour, a factor that has left a major gap between SoftBank’s market capitalization and the sum of its investments.


TOKYO — SoftBank Group’s Vision Fund is turning to a new strategy as a global pandemic and government stimulus distort tech valuations: Invest smaller in hopes for bigger returns.

After raising nearly $100 billion and investing $85 billion in high-profile companies like Uber Technologies, WeWork and ByteDance over three years, the Vision Fund is now focusing on making smaller bets in early-stage startups.

Among the investments it has led are $100 million in Zhangmen, a Chinese online education startup; $150 million in Unacademy, an Indian peer; and $100 million in Biofourmis, a U.S. startup that tracks health data using wearable devices. In total, it has approved 19 investments worth $3.5 billion for “Vision Fund 2” — a vehicle currently funded entirely by SoftBank.

Over the next few months, medical delivery drones will take flight in the Netherlands between two hospitals to deliver emergency medicines, blood, and other time-sensitive samples. The drones will be flying between the Isala Diaconessenhuis Meppel hospital and the Isala Ziekenhuis hospital.

The drones are at the center of tests, looking at how they can deliver emergency medicine in the future and improve patient care. This also marks the first time drones have flown beyond visual line of sight (BVLOS) in overpopulated areas.

The tests are being run by the Medical Drone Service, an initiative set up by ANWB, PostNL, Erasmus MC, Isala, Sanquin, Certe, and technology partners Avy and KPN.